Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Buys 4,500 Shares of Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur bought 4,500 shares of the company’s stock in a transaction dated Tuesday, December 24th. The shares were acquired at an average cost of $4.65 per share, for a total transaction of $20,925.00. Following the completion of the transaction, the chief executive officer now owns 3,270,924 shares of the company’s stock, valued at approximately $15,209,796.60. The trade was a 0.14 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ron Bentsur also recently made the following trade(s):

• On Friday, November 15th, Ron Bentsur acquired 20,000 shares of Nuvectis Pharma stock. The shares were acquired at an average price of $4.92 per share, for a total transaction of $98,400.00.

Nuvectis Pharma Trading Up 8.0 %

Nuvectis Pharma stock opened at $5.02 on Friday. The stock has a 50 day moving average of $6.29 and a 200-day moving average of $6.47. The stock has a market cap of $96.99 million, a P/E ratio of -4.33 and a beta of 0.20. Nuvectis Pharma, Inc. has a 52 week low of $4.44 and a 52 week high of $12.10.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.01. During the same quarter last year, the business earned ($0.37) EPS. As a group, equities analysts predict that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.

Institutional Trading of Nuvectis Pharma

Several institutional investors and hedge funds have recently bought and sold shares of NVCT. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Nuvectis Pharma in the 2nd quarter worth approximately $58,000. Nations Financial Group Inc. IA ADV acquired a new position in Nuvectis Pharma in the third quarter worth $63,000. GSA Capital Partners LLP increased its stake in Nuvectis Pharma by 3.7% during the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock valued at $315,000 after purchasing an additional 1,790 shares during the last quarter. Iridian Asset Management LLC CT acquired a new stake in shares of Nuvectis Pharma during the third quarter worth $348,000. Finally, Renaissance Technologies LLC lifted its position in shares of Nuvectis Pharma by 20.7% in the 2nd quarter. Renaissance Technologies LLC now owns 74,500 shares of the company’s stock worth $472,000 after buying an additional 12,800 shares during the last quarter. Institutional investors and hedge funds own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.